• Lyonbiopole
  • Lyonbiopole missions
  • The Lyonbiopole team
  • Governance
    • Board of Directors
    • Members of the Board
  • The technical group, Gtech
  • Our public funders
  • Our members and associated members
  • Press area
    • Press releases
    • Communication tools
    • Mobile app
  • Become a member
  • Contact us
• Research and innovation
  • Goals
  • R&D project support
    • Setting up and funding a project
    • Project accreditation
    • Supporting a European project
    • Project monitoring
  • Scientific coordination
    • Partnering Day
    • The Microbiota and Health Day
    • Workshops and topicaldays
  • Project funding
    • Lyonbiopole actions
    • Calls for projects
  • Clinical innovation
  • Structuring program
    • MabDesign
  • Upcoming events
• Economic development
  • Goals
  • Private investment
    • Private Inv€stments Day
    • Inv€stor Meetings
  • Access to skills
    • GPEC and training initiatives
    • Intellectual property and consortium agreements
  • Networking
    • Lunch Break Partnering
    • Open Innovation Meetings
    • Life science directory
  • Upcoming events
• International
  • Goals
  • Europe
    • The support offer to Europe
    • Main European funding
    • Our clusters partners
    • Our European projects
  • International funding tools
    • The International Representation and Expertise Programme – IREP
    • ITPP
    • Cooperation with the CQDM
  • Our international trade missions
  • Upcominig events
• Facilities
  • Our labs offer
  • Our offices offer
  • Contact-us
• Directories
  • Companies
  • Consultants & Service providers
  • Research units
  • Healthcare institutions
  • Collaborative Clinical Research Structures
  • R&D projects
• Diary – News
  • Upcoming events
    • All events
    • Our events
    • In partnership
    • Around our themes
  • News
    • All news
    • Lyonbiopole
    • Our members
    • Focus on
    • New members
    • Blog
  • Newsletter
  • Lyonbiopole in action

 

PX’Therapeutics, a subsidiary of the Aguettant group, a company that specializes in the customer-tailored development of recombinant proteins, and RELIEF THERAPEUTICS Holding AG (“Relief”,SIX:RLF), a biotechnology company dedicated to the clinical development of innovative molecules for the treatment of certain diabetes-related complications, respiratory disorders and rare diseases, have announced today a strategic collaboration agreement for the production of atexakin alfa, a low-dose formulation of the recombinant human protein interleukin 6.